Aradigm to Present at 9th Annual Biotech Showcase Conference on January 9

Press Releases

<< Back
Jan 06, 2017

Aradigm to Present at 9th Annual Biotech Showcase Conference on January 9

HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda, Ph.D., will present an overview of the Company at the 9th Annual Biotech Showcase Conference on Monday, January 9, 2017, at 5:00 p.m. Pacific time. The event will be held at the Hilton San Francisco Union Square, San Francisco, California.

Interested parties can access a live audio webcast and slide presentation at An archived presentation and the presentation slides will be available on the Company's Web site for 30 days.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Aradigm is completing Phase 3 development of Pulmaquin® (an investigational proprietary formulation of ciprofloxacin for inhalation) for the treatment of non-cystic fibrosis bronchiectasis. Aradigm's inhaled ciprofloxacin formulations including Pulmaquin are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax. In addition, Aradigm has a pipeline composed of programs to prevent diseases in tobacco smokers through smoking cessation and a diagnostic program to detect aspirations of gastrointestinal fluid into the respiratory tract. More information about Aradigm can be found at

Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.

Aradigm Corporation
Nancy Pecota, 510-265-8800
Chief Financial Officer

Source: Aradigm Corporation

News Provided by Acquire Media

CONTACT NEWS & EVENTS LEGAL SITE MAP ©2018 Aradigm Corporation. All Rights Reserved.